This study is exploring a new way to help people with breast or gynecological cancers who experience cognitive difficulties, often referred to as "chemo brain." The focus is on a special headband that contains tiny semiconductor devices which may help improve these cognitive challenges. By testing this headband, the study aims to see if it is a safe and effective tool for easing the mental fog that can accompany cancer treatment. This research could potentially offer a non-invasive option to improve quality of life for those affected by cognitive impairment related to cancer. Participants in the study will take part in two main phases. Initially, they will be randomly given either an active headband with the semiconductor or a lookalike headband without the active component, wearing it for 18 hours each day over three weeks. After this first phase, there is a two-week break called a "washout period" where no headbands are worn. This helps clear any effects from the initial headband. Following this break, participants switch headbands, wearing the opposite headband for another three weeks. This design helps researchers compare the effects of the real headband against the sham version to determine its true effectiveness and safety.
Inclusion Criteria: * Participant aged 18 years or older. * Diagnosis of breast or gynecologic cancer. * Participant has completed chemotherapy within 90 days of enrollment and no additional chemotherapy is planned for the duration of study treatment. * Perceived cognitive impairment (PCI) score of \< 63 in the FACT-Cog-PCI assessment. * Ability to wear device for at least 18 hours per day during the 6 weeks of intervention. * ECOG Performance Status ≤ 3. * Able to speak and understand English. * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: * History of neurodegenerative conditions, including but not limited to multiple sclerosis, dementia, Alzheimer's, or Parkinson's disease. * History of CNS diseases such as stroke, meningitis, or traumatic brain injury within 12 months of enrollment. * Poorly controlled psychological disorders including alcohol dependence, major depressive disorder, schizophrenia, or bipolar disorder. * Use of tobacco or nicotine products within 90 days of enrollment. * The diagnosis of another malignancy ≤ 12 months before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration per treating investigator (i.e., basal cell or squamous cell skin cancer). * Known brain metastases or cranial epidural disease. * History of poorly controlled diabetes in the opinion of the investigator. * Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures. * Active infection requiring systemic therapy. * Participants taking prohibited medications as described in Section 6.5.1. Cautionary medications may be used as described in Section 6.5.2.
are designated in this study
of being blinded to the placebo group